Arabic Arabic English English French French German German

Potential marker for success of immunotherapy in the treatment of lung cancer

Lung cancer has the highest mortality rate of all cancers, and treatment options are extremely limited, especially for patients with oncogenic mutations in the KRAS gene. A great deal of hope was invested in the licensing of immune checkpoint inhibitors, but the reality is that some patients respond very well to this treatment while it is completely ineffective in others. In a paper just published in Science Translational Medicine, a MedUni Vienna research group led by Herwig Moll (Center for Physiology and Pharmacology) identified a potential marker for the success of immunotherapy in lung cancer patient and explained the underlying molecular processes. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Two treatments for autism found to help toddlers equally

Next Post

Global Covid deaths cross 4 mn as outbreaks surge in Asia

Related Posts